News und Analysen

Abbott Laboratories (NYSE: ABT) is seen as a solid safe-harbor stock because of the company's 135-year history, its diversified healthcare business, and its reliable dividend.

The company is known

There are many ways one can become richer, from trying to buy a winning lottery ticket to pouncing on some get-rich-quick scheme. Unfortunately, none of these methods is very reliable at all, unlike

Pharmaceutical giant Merck (NYSE: MRK) has delivered excellent returns to its shareholders over the past 12 months, as last year's downturn did little to slow the drugmaker. The company's solid

Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence. The clinical-stage bio

Stock valuations are at historically high levels. However, that doesn't mean you can't find stocks worth buying.

Three Motley Fool contributors identified bargain stocks to buy in a market that's

If you're an income investor, you may have heard tales of mighty companies that have raised their payouts no matter the economic cycle. Only 49 companies over the past 50 years have managed to

Medtronic (NYSE: MDT) is one of the largest medical equipment makers in the world with 95,000 employees across 150 countries and a market capitalization of $108 billion. The company's stock is up a

Dividends are great. They're a reliable source of passive income for retirees (and others) or can help boost long-term returns for investors who choose to reinvest them. But what happens when a

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

You don't have to invest in artificial intelligence or the latest tech company to earn great returns on your investments. The healthcare industry is full of promising investment opportunities of its

Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The US harvests

A notable price target cut from an analyst was followed by a dip in the price of DexCom (NASDAQ: DXCM) stock on Friday. Investors traded out of the specialty medical device maker, reducing its value

The elite club of Dividend Kings arguably stands out as the market's most prestigious group of dividend payers. Companies must have raised their payouts for at least 50 consecutive years to join, a

Healthcare stocks, often considered recession-proof, have lagged most other sectors of the market so far this year. While the S&P 500 index is up by more than 16% and flirting with a return to bull

Abbott Laboratories (NYSE: ABT) is a leading healthcare company with a global presence. It has a diverse business with four key segments: established pharmaceuticals, diagnostics, nutrition, and

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) fell more than 13% on Thursday. The biotech company, which specializes in using tumor-infiltrating lymphocyte (TIL) therapies to fight cancer, has

When investing in equities, even a relatively modest initial sum such as $500 can go a long way, provided investors pick the right stocks and continue adding to their positions regularly. Let's

Do you want to lock in a high-yielding dividend stock? You might consider those that are struggling and near their 52-week lows. While stock prices typically drop because of problems with the

Innovation never sleeps in the healthcare sector. At the beginning of this year, there had never been a vaccine approved by the U.S. Food and Drug Administration (FDA) for the prevention of the

The market hasn't yet entered bull territory, but it's getting close. The S&P 500 already rose more than 20% from its bear market low -- now, it just has to reach a new high, and the next bull